Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients

Clinica Chimica Acta

Volumn 460, Issue , 2016, Pages 178-183

  Sangoi, Manuela Borges ^a,b   de Carvalho, José Antonio M ^a   Tatsch, Etiane ^a   Hausen, Bruna S ^a   Bollick, Yãnaí S ^a   Londero, Sílvia W K ^a   Duarte, Thiago ^a   Scolari, Rogério ^c   Duarte, Marta M M F ^a,c,d   Premaor, Melissa O ^a   Comim, Fabio V ^a   Moretto, Maria B ^a   Moresco, Rafael N ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b Integrated Regional University of High Uruguay and Missions   (Brazil)

^c Clinical Analysis Laboratory   (Brazil)

^d UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Cytokines; Diabetic kidney disease; Inflammation; Urine

Indexed keywords

CREATININE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE;

ADULT; ALBUMIN URINE LEVEL; ALBUMINURIA; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; HUMAN; KIDNEY INJURY; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINARY EXCRETION; URINE LEVEL; COHORT ANALYSIS; COMPLICATION; DIABETIC NEPHROPATHIES; INFLAMMATION; MIDDLE AGED; URINE;

ADULT; BIOMARKERS; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; MIDDLE AGED;

EID: 84977663145     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.06.028     Document Type: Article

References (35)

1. [1] Mora-Fernández, C., Domínguez-Pimentel, V., de Fuentes, M.M., Górriz, J.L., Martínez-Castelao, A., Navarro-González, J.F., Diabetic kidney disease: from physiology to therapeutics. J. Physiol. 592 (2014), 3997–4012.
2. [2] Atkins, R.C., The epidemiology of chronic kidney disease. Kidney Int. Suppl. 67 (2005), S14–S18.
3. [3] Luis-Rodríguez, D., Martínez-Castelao, A., Górriz, J.L., De-Álvaro, F., Navarro-González, J.F., Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J. Diabetes 3 (2012), 7–18.
4. [4] Gonzalez Suarez, M.L., Thomas, D.B., Barisoni, L., Fornoni, A., Diabetic nephropathy: is it time yet for routine kidney biopsy?. World J. Diabetes 4 (2013), 245–255.
5. [5] Lee, S.Y., Choi, M.E., Urinary biomarkers for early diabetic nephropathy: beyond albuminuria. Pediatr. Nephrol. 30 (2014), 1063–1075.
6. [6] Steinke, J.M., Sinaiko, A.R., Kramer, M.S., Suissa, S., Chavers, B.M., Mauer, M., The early natural history of nephropathy in Type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54 (2005), 2164–2171.
7. [7] Matheson, A., Willcox, M.D., Flanagan, J., Walsh, B.J., Urinary biomarkers in type 2 diabetes: a review. Diabetes Metab. Res. Rev. 26 (2010), 150–171.
8. [8] Moresco, R.N., Sangoi, M.B., de Carvalho, J.A.M., Tatsch, E., Bochi, G.V., Diabetic nephropathy: traditional to proteomic markers. Clin. Chim. Acta 421 (2013), 17–30.
9. [9] Navarro-González, J.F., Mora-Fernández, C., The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19 (2008), 433–442.
10. [10] Lim, A.K.H., Tesch, G.H., Inflammation in diabetic nephropathy. Mediat. Inflamm., 2012, 2012, 10.1155/2012/146154.
11. [11] Misseri, R., Meldrum, D.R., Dinarello, C.A., Dagher, P., Hile, K.L., Rink, R.C., et al. TNF-alpha mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. Am. J. Physiol. Ren. Physiol. 288 (2005), F406–F411.
12. [12] García-García, P.M., Getino-Melián, M.A., Domínguez-Pimentel, V., Navarro-González, J.F., Inflammation in diabetic kidney disease. World J. Diabetes 15 (2014), 431–443.
13. [13] Dalla Vestra, M., Mussap, M., Gallina, P., Bruseghin, M., Cernigoi, A.M., Saller, A., et al. Acute-phase markers markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16 (2005), S78–S82.
14. [14] Herder, C., Carstensen, M., Ouwens, D.M., Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes. Metab. 15 (2013), 39–50.
15. [15] Zamauskaite, A., Yaqoob, M.M., Madrigal, J.A., Cohen, S.B., The frequency of Th2 type cells increases with time on peritoneal dialysis in patients with diabetic nephropathy. Eur. Cytokine Netw. 10 (1999), 219–226.
16. [16] Mysliwska, J., Zorena, K., Semetkowska-Jurkiewicz, E., Rachon, D., Suchanek, H., Mysliwski, A., High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur. Cytokine Netw. 16 (2005), 117–122.
17. [17] Wu, J., Ding, Y., Zhu, C., Shao, X., Xie, X., Lu, K., et al. Urinary TNF‑α and NGAL are correlated with the progression of nephropathy in patients with type 2 diabetes. Exp. Ther. Med. 6 (2013), 1482–1488.
18. [18] Navarro, J.F., Mora-Fernández, C., The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 17 (2006), 441–450.
19. [19] Wolkow, P.P., Niewczas, M.A., Perkins, B., Ficociello, L.H., Lipinski, B., Warram, J.H., et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J. Am. Soc. Nephrol. 19 (2008), 789–797.
20. [20] Cherney, D.Z., Scholey, J.W., Daneman, D., Dunger, D.B., Dalton, R.N., Moineddin, R., et al. Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet. Med. 29 (2012), 1297–1302.
21. [21] American Diabetes Association, Standards of medical care in diabetes – 2014. Diabetes Care 37 (2014), S14–S80.
22. [22] Matsushita, K., van der Velde, M., Astor, B.C., Woodward, M., Levey, A.S., de Jong, P.E., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
23. [23] Wheeler, D.C., Becker, G.J., Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int. 83 (2013), 377–383.
24. [24] Larsen, K., Creatinine assay by a reaction-kinetic principle. Clin. Chim. Acta 41 (1972), 209–217.
25. [25] Newman, D.J., Pugia, M.J., Lott, J.A., Wallace, J.F., Hiar, A.M., Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin. Chim. Acta 294 (2000), 139–155.
26. [26] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150 (2009), 604–612.
27. [27] Duran-Salgado, M.B., Rubio-Guerra, A.F., Diabetic nephropathy and inflammation. World J. Diabetes 5 (2014), 393–398.
28. [28] Navarro, J.F., Mora, C., Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal 6 (2006), 908–917.
29. [29] Shikano, M., Sobajima, H., Yoshikawa, H., Toba, T., Kushimoto, H., Katsumata, H., et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85 (2000), 81–85.
30. [30] Navarro, J.F., Mora, C., Muros, M., García, J., Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 21 (2006), 3428–3434.
31. [31] Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52 (2003), 605–608.
32. [32] El Mesallamy, H.O., Ahmed, H.H., Bassyouni, A.A., Ahmed, A.S., Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin. Biochem. 45 (2012), 646–650.
33. [33] Wu, C.C., Chen, J.S., Lu, K.C., Chen, C.C., Lin, S.H., Chu, P., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin. Chim. Acta 411 (2010), 700–704.
34. [34] Nauta, F.L., Boertien, W.E., Bakker, S.J.L., Van Goor, H., Van Oeveren, W., de Jong, P.E., et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34 (2011), 975–981.
35. [35] De Carvalho, J.A.M., Tatsch, E., Hausen, B.S., Bollick, Y.S., Moretto, M.B., Duarte, T., et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin. Biochem. 49 (2016), 232–236.